Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(3.71)
# 628
Out of 4,412 analysts
14
Total ratings
50%
Success rate
11.15%
Average return
Main Sectors:
Top Industries:
13 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Initiates: Neutral | n/a | $52.05 | - | 1 | Apr 23, 2024 | |
| AGIO Agios Pharmaceuticals | Reiterates: Overweight | n/a | $32.50 | - | 1 | Apr 9, 2024 | |
| TNGX Tango Therapeutics | Initiates: Overweight | n/a | $7.70 | - | 1 | Apr 4, 2024 | |
| RNA Avidity Biosciences | Initiates: Overweight | $60 | $24.13 | +148.65% | 1 | Mar 14, 2024 | |
| BIIB Biogen | Reiterates: Overweight | $311 | $214.82 | +44.77% | 2 | Feb 20, 2024 | |
| IMTX Immatics | Initiates: Overweight | n/a | $9.93 | - | 1 | Nov 2, 2023 | |
| IMCR Immunocore Holdings | Initiates: Overweight | n/a | $59.08 | - | 1 | Nov 2, 2023 | |
| BLUE bluebird bio | Initiates: Neutral | n/a | $0.89 | - | 1 | Oct 17, 2023 | |
| CRSP CRISPR Therapeutics AG | Downgrades: Neutral | n/a | $52.99 | - | 1 | Oct 17, 2023 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $370 | $392.81 | -5.81% | 1 | Oct 17, 2023 | |
| EDIT Editas Medicine | Downgrades: Neutral | n/a | $5.21 | - | 1 | Oct 17, 2023 | |
| GTHX G1 Therapeutics | Initiates: Outperform | n/a | $3.77 | - | 1 | Jun 12, 2017 | |
| OVID Ovid Therapeutics | Initiates: Outperform | n/a | $3.05 | - | 1 | May 30, 2017 |
Incyte
Apr 23, 2024
Initiates: Neutral
Price Target: n/a
Current: $52.05
Upside: -
Agios Pharmaceuticals
Apr 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $32.50
Upside: -
Tango Therapeutics
Apr 4, 2024
Initiates: Overweight
Price Target: n/a
Current: $7.70
Upside: -
Avidity Biosciences
Mar 14, 2024
Initiates: Overweight
Price Target: $60
Current: $24.13
Upside: +148.65%
Biogen
Feb 20, 2024
Reiterates: Overweight
Price Target: $311
Current: $214.82
Upside: +44.77%
Immatics
Nov 2, 2023
Initiates: Overweight
Price Target: n/a
Current: $9.93
Upside: -
Immunocore Holdings
Nov 2, 2023
Initiates: Overweight
Price Target: n/a
Current: $59.08
Upside: -
bluebird bio
Oct 17, 2023
Initiates: Neutral
Price Target: n/a
Current: $0.89
Upside: -
CRISPR Therapeutics AG
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $52.99
Upside: -
Vertex Pharmaceuticals
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $392.81
Upside: -5.81%
Editas Medicine
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $5.21
Upside: -
G1 Therapeutics
Jun 12, 2017
Initiates: Outperform
Price Target: n/a
Current: $3.77
Upside: -
Ovid Therapeutics
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $3.05
Upside: -